66
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021

      research-article
      , PhD 1 , 2 , , , MS 1 , 3 , , MPH 1 , , MSPH 1 , , MPH 1 , 3 , 1 , , MPH 1 , , MPH 1 , , MPH 1 , , MSPH 1 , , MPH 1 , 3 , , MPH 1 , , PhD 1 , , MD 4 , 5 , , MD 4 , 6 , , MPH 7 , , MPH 7 , , MPH 8 , , MPH 8 , , MD 9 , 10 , 11 , , DrPH 9 , 10 , 11 , , MPH 12 , , LMSW 12 , , MPH 13 , , MPH 13 , , MPH 14 , , MPH 14 , , PhD 15 , 16 , , MPH 17 , , MPH 17 , , MD 18 , , MPH 19 , , MPH 20 , , MPH 20 , , MD 21 , , MD 21 , , MD 22 , , MD 22 , , MPH 23 , 24 , , DVM 1 , , MD 1 , , MD 1 , , DSc 1 , , MD 1 , * , , MD 1 , * , COVID-NET Surveillance Team COVID-NET Surveillance Team COVID-NET Surveillance Team , , , , , , , , , , , , , , , , ,
      Morbidity and Mortality Weekly Report
      Centers for Disease Control and Prevention

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although COVID-19–associated hospitalizations and deaths have occurred more frequently in adults, † COVID-19 can also lead to severe outcomes in children and adolescents ( 1 , 2 ). Schools are opening for in-person learning, and many prekindergarten children are returning to early care and education programs during a time when the number of COVID-19 cases caused by the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, is increasing. § Therefore, it is important to monitor indicators of severe COVID-19 among children and adolescents. This analysis uses Coronavirus Disease 2019–Associated Hospitalization Surveillance Network (COVID-NET) ¶ data to describe COVID-19–associated hospitalizations among U.S. children and adolescents aged 0–17 years. During March 1, 2020–August 14, 2021, the cumulative incidence of COVID-19–associated hospitalizations was 49.7 per 100,000 children and adolescents. The weekly COVID-19–associated hospitalization rate per 100,000 children and adolescents during the week ending August 14, 2021 (1.4) was nearly five times the rate during the week ending June 26, 2021 (0.3); among children aged 0–4 years, the weekly hospitalization rate during the week ending August 14, 2021, was nearly 10 times that during the week ending June 26, 2021.** During June 20–July 31, 2021, the hospitalization rate among unvaccinated adolescents (aged 12–17 years) was 10.1 times higher than that among fully vaccinated adolescents. Among all hospitalized children and adolescents with COVID-19, the proportions with indicators of severe disease (such as intensive care unit [ICU] admission) after the Delta variant became predominant (June 20–July 31, 2021) were similar to those earlier in the pandemic (March 1, 2020–June 19, 2021). Implementation of preventive measures to reduce transmission and severe outcomes in children is critical, including vaccination of eligible persons, universal mask wearing in schools, recommended mask wearing by persons aged ≥2 years in other indoor public spaces and child care centers, †† and quarantining as recommended after exposure to persons with COVID-19. §§ COVID-NET conducts population-based surveillance for laboratory-confirmed COVID-19–associated hospitalizations in 99 counties across 14 states ¶¶ ( 1 ). Residents of the surveillance catchment area who received positive molecular or rapid antigen detection test results for SARS-CoV-2 during hospitalization or within 14 days before admission were classified as having COVID-19–associated hospitalizations. Unadjusted age-specific cumulative and weekly COVID-19–associated hospitalization rates (hospitalizations per 100,000 children and adolescents residing in the catchment area) during March 1, 2020–August 14, 2021, were calculated by dividing the total number of hospitalized patients by the National Center for Health Statistics’ population estimates within each age group for the counties included in the surveillance catchment area.*** Among adolescents, who are currently eligible for vaccination ††† ( 3 ), age-specific hospitalization rates during June 20–July 31, 2021, were calculated by COVID-19 vaccination status, which was determined for both hospitalized patients and the catchment area population using state immunization information systems data. §§§ Because the number of fully vaccinated persons in the underlying population changed weekly, incidence (cases per 100,000 person-weeks) was calculated by dividing the total number of vaccinated hospitalized adolescents by the sum of vaccinated adolescents in the underlying population each week; the same method was used to calculate incidence among unvaccinated adolescents. ¶¶¶ Rate ratios and 95% confidence intervals (CIs) were calculated. Trained surveillance staff members conducted medical chart abstractions for all pediatric COVID-NET patients using a standardized case report form. Data on the following measures of severe disease were collected: median hospital length of stay, ICU admission, highest level of respiratory support received (i.e., invasive mechanical ventilation [IMV], bilevel positive airway pressure or continuous positive airway pressure, or high-flow nasal cannula), vasopressor use, and in-hospital death. Deaths occurring after hospital discharge were not included in this analysis. To assess COVID-19 severity among hospitalized children and adolescents in the setting of widespread Delta variant circulation, the proportions with measures of severe disease were compared between the periods before (March 1, 2020–June 19, 2021) and after (June 20–July 31, 2021) the Delta variant became the predominant strain circulating in the United States**** ( 4 ). A Wilcoxon rank sum test was used to compare medians; chi square or Fisher’s exact tests were used to compare proportions. Data were analyzed using SAS (version 9.4; SAS Institute); statistical significance was defined as p<0.05. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. †††† During March 1, 2020–August 14, 2021, COVID-NET identified 49.7 cumulative COVID-19–associated hospitalizations per 100,000 children and adolescents (Figure 1); rates were highest among children aged 0–4 years (69.2) and adolescents aged 12–17 years (63.7) and lowest among children aged 5–11 years (24.0). Weekly hospitalization rates were at their lowest in 2021 during the weeks ending June 12–July 3 (0.3 per 100,000 children and adolescents each week) (Figure 2). During a subsequent 6-week period after the Delta variant became predominant, rates rose each week to 1.4 during the week ending August 14, 2021, which was 4.7 times the rate during the week ending June 26, 2021 and approached the peak hospitalization rate of 1.5 observed during the week ending January 9, 2021. §§§§ Weekly rates increased among all age groups; the sharpest increase occurred among children aged 0–4 years, for whom the rate during the week ending August 14, 2021 (1.9) was nearly 10 times that during the week ending June 26, 2021 (0.2). During June 20–July 31, 2021, among 68 adolescents hospitalized with COVID-19 whose vaccination status had been ascertained, 59 were unvaccinated, five were partially vaccinated, and four were fully vaccinated; the hospitalization rate among unvaccinated adolescents was 0.8 per 100,000 person-weeks (95% CI = 0.6–0.9), compared with 0.1 (95% CI = 0.0–0.1) in fully vaccinated adolescents (rate ratio = 10.1; 95% CI = 3.7–27.9). FIGURE 1 COVID-19–associated cumulative hospitalizations per 100,000 children and adolescents,* by age group — COVID-NET, 14 states, † March 1, 2020–August 14, 2021 * Rates are subject to change as additional data are reported. † Select counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. Figure is a line chart showing COVID-19–associated cumulative hospitalization rates per 100,000 children and adolescents, by age group, in select counties in 14 states according to COVID-NET, during March 1, 2020–August 14, 2021. FIGURE 2 COVID-19–associated weekly hospitalizations per 100,000 children and adolescents,* by age group — COVID-NET, 14 states, † March 1, 2020–August 14, 2021 (3-week smoothed running averages) § * Rates are subject to change as additional data are reported. † Select counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. § Smoothed running averages are used for visualization purposes only. Figure is a line chart showing 3-week smoothed running averages of COVID-19–associated weekly hospitalizations per 100,000 persons, by age group, in select counties in 14 states according to COVID-NET, during March 1, 2020–August 14, 2021. Among 3,116 hospitalized children and adolescents with COVID-19 during March 1, 2020–June 19, 2021, for whom complete clinical data were available, ¶¶¶¶ 827 (26.5%) were admitted to an ICU, 190 (6.1%) required IMV, and 21 (0.7%) died. Among 164 hospitalized children and adolescents with COVID-19 during June 20–July 31, 2021, for whom complete clinical data were available,***** 38 (23.2%) were admitted to an ICU, 16 (9.8%) required IMV, and three (1.8%) died. The differences in these indicators of severe disease between the two periods were not statistically significant (Table). TABLE Clinical interventions and outcomes among children and adolescents aged 0-17 years during COVID-19–associated hospitalizations — COVID‑NET, 14 states,* March 1, 2020–June 19, 2021 and June 20–July 31, 2021 Interventions and outcomes Children and adolescents hospitalized, No. (%) p-value§ March 1, 2020–June 19, 2021 (N = 3,116)† June 20–July 31, 2021 (N = 164)† Hospital length of stay, median (interquartile range) 3 (2–5) 2 (1–4) 0.01 Outcome Died during hospitalization 21 (0.7) 3 (1.8) 0.12 ICU admission 827 (26.5) 38 (23.2) 0.34 Vasopressor support 233 (7.5) 13 (7.9) 0.83 Highest level of respiratory support ¶ High flow nasal cannula 162 (5.2) 13 (7.9) 0.13 BiPAP/CPAP 131 (4.2) 6 (3.7) 0.73 Invasive mechanical ventilation 190 (6.1) 16 (9.8) 0.06 Abbreviations: BiPAP = bilevel positive airway pressure; CPAP = continuous positive airway pressure; ICU = intensive care unit. * Select counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. † Includes those with complete clinical data on hospital length of stay, ICU admission, highest level of respiratory support (invasive mechanical ventilation, BiPAP/CPAP, or high flow nasal cannula), vasopressor support, and disposition discharge (i.e., discharged alive or died in-hospital). § Medians were compared using a Wilcoxon rank sum test. Proportions were compared using chi square tests. The proportions who died during hospitalization were compared using Fisher’s exact test. ¶ Highest level of respiratory support for each patient that needed respiratory support. Discussion Weekly COVID-19–associated hospitalization rates rose rapidly during late June to mid-August 2021 among U.S. children and adolescents aged 0–17 years; by mid-August, the rate among children aged 0–4 years was nearly 10 times the rate 7 weeks earlier. This increase coincides with widespread circulation of the highly transmissible Delta variant. COVID-NET data indicate that vaccination was highly effective in preventing COVID-19–associated hospitalizations in adolescents during late June to late July 2021. Since March 2020, approximately one in four hospitalized children and adolescents with COVID-19 has required intensive care, although the proportions with indicators of severe disease during the period when the Delta variant predominated were generally similar compared with those earlier in the pandemic. The observed indicators of severe COVID-19 among children and adolescents, as well as the potential for serious longer-term sequelae (e.g., multisystem inflammatory syndrome in children) documented elsewhere ( 5 , 6 ), underscore the importance of implementing multipronged preventive measures to reduce severe COVID-19 disease, including nonpharmaceutical interventions and vaccination among eligible age groups. ††††† Among adolescents aged 12–17 years, the only pediatric age group for whom a COVID-19 vaccine is currently approved, hospitalization rates were approximately 10 times higher in unvaccinated compared with fully vaccinated adolescents, indicating that vaccines were highly effective at preventing serious COVID-19 illness in this age group during a period when the Delta variant predominated. As of July 31, 2021, 32% of U.S. adolescents had completed a COVID-19 vaccination series ( 7 ); increasing vaccination coverage among adolescents, as well as expanding eligibility for COVID-19 vaccination to younger age groups if approved and recommended, is expected to reduce severe COVID-19–associated outcomes among children and adolescents. Similar to another recent analysis, COVID-NET data suggest that indicators of severe disease among hospitalized children during an early period when the Delta variant predominated were generally similar to those observed earlier in the pandemic ( 8 ). Trends in outcomes will need to be monitored closely as more data become available. For example, whereas the point estimate of the proportion of hospitalized children who required IMV during the period of Delta predominance (9.8%) was higher than that earlier in the pandemic (6.1%), the comparison of these proportions was based on a relatively small number of children (16) requiring IMV during the period of Delta predominance, and the difference was not statistically significant (p = 0.06). Further, surveillance data limited to hospitalized persons cannot be used to assess whether increases in COVID-19–associated hospitalization rates among children and adolescents are due to increased community SARS-CoV-2 transmission or increased disease severity caused by the Delta variant. The findings in this report are subject to at least five limitations. First, children and adolescents meeting COVID-NET criteria with a positive SARS-CoV-2 test result might have been hospitalized primarily for reasons other than COVID-19 ( 2 ), resulting in potential overestimations of hospitalization rates. Second, COVID-19–associated hospitalizations might have been missed because of testing practices and test availability. Third, the number of hospitalized children with severe outcomes was small during June 20–July 31, 2021, limiting comparisons between periods before and during Delta variant predominance. Fourth, the number of fully vaccinated hospitalized adolescents remained low at the time of reporting, and hospitalization rates stratified by vaccination status are subject to error if misclassification of vaccination status occurred. Finally, the COVID-NET catchment areas include approximately 10% of the U.S. population; thus, findings might not be nationally generalizable. Rates of COVID-19–associated hospitalization among children and adolescents increased rapidly from late June to mid-August 2021, coinciding with predominance of the Delta variant. With more activities resuming, including in-person school attendance and a return of younger children to congregate child care settings, preventive measures to reduce the incidence of severe COVID-19 are critical. Universal indoor masking is recommended for all teachers, staff members, students, and visitors in kindergarten through grade 12 schools, regardless of vaccination status. §§§§§ CDC recommends that persons aged ≥2 years who are unvaccinated, as well as vaccinated persons in areas of substantial or high transmission, wear masks in all indoor public spaces. ¶¶¶¶¶ CDC also recommends that child care centers serving children too young to be vaccinated consider implementing universal indoor masking for persons aged ≥2 years.****** All persons who are eligible should receive COVID-19 vaccines to reduce the risk for severe disease for themselves and others with whom they come into contact, including children who are currently too young to be vaccinated. Summary What is already known about this topic? COVID-19 can cause severe illness in children and adolescents. What is added by this report? Weekly COVID-19–associated hospitalization rates among children and adolescents rose nearly five-fold during late June–mid-August 2021, coinciding with increased circulation of the highly transmissible SARS-CoV-2 Delta variant. The proportions of hospitalized children and adolescents with severe disease were similar before and during the period of Delta predominance. Hospitalization rates were 10 times higher among unvaccinated than among fully vaccinated adolescents. What are the implications for public health practice? Preventive measures to reduce transmission and severe outcomes in children and adolescents are critical, including vaccination, universal masking in schools, and masking by persons aged ≥2 years in other indoor public spaces and child care centers.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

          Abstract Background Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome. Methods We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms. Results We report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were documented in 15 patients (8%), and Kawasaki’s disease–like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%). Conclusions Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1–July 25, 2020

            Most reported cases of coronavirus disease 2019 (COVID-19) in children aged <18 years appear to be asymptomatic or mild ( 1 ). Less is known about severe COVID-19 illness requiring hospitalization in children. During March 1–July 25, 2020, 576 pediatric COVID-19 cases were reported to the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system that collects data on laboratory-confirmed COVID-19–associated hospitalizations in 14 states ( 2 , 3 ). Based on these data, the cumulative COVID-19-associated hospitalization rate among children aged <18 years during March 1–July 25, 2020, was 8.0 per 100,000 population, with the highest rate among children aged <2 years (24.8). During March 21–July 25, weekly hospitalization rates steadily increased among children (from 0.1 to 0.4 per 100,000, with a weekly high of 0.7 per 100,000). Overall, Hispanic or Latino (Hispanic) and non-Hispanic black (black) children had higher cumulative rates of COVID-19–associated hospitalizations (16.4 and 10.5 per 100,000, respectively) than did non-Hispanic white (white) children (2.1). Among 208 (36.1%) hospitalized children with complete medical chart reviews, 69 (33.2%) were admitted to an intensive care unit (ICU); 12 of 207 (5.8%) required invasive mechanical ventilation, and one patient died during hospitalization. Although the cumulative rate of pediatric COVID-19–associated hospitalization remains low (8.0 per 100,000 population) compared with that among adults (164.5),* weekly rates increased during the surveillance period, and one in three hospitalized children were admitted to the ICU, similar to the proportion among adults. Continued tracking of SARS-CoV-2 infections among children is important to characterize morbidity and mortality. Reinforcement of prevention efforts is essential in congregate settings that serve children, including childcare centers and schools. COVID-NET conducts population-based surveillance for laboratory-confirmed COVID-19–associated hospitalizations in 99 counties † in 14 states (California, Connecticut, Colorado, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah), representing all 10 U.S. Department of Health and Human Services regions ( 2 , 3 ). Laboratory-confirmed COVID-19–associated hospitalizations among residents in a predefined surveillance catchment area who had a positive SARS-CoV-2 molecular test during hospitalization or up to 14 days before admission are included in surveillance. SARS-CoV-2 tests are ordered at the discretion of the treating health care provider. Trained surveillance officers perform medical chart abstractions for all identified cases. Patients aged <18 years hospitalized with COVID-19 during March 1–July 25, 2020, were included in this analysis. Weekly and cumulative COVID-19–associated hospitalization rates were calculated using the number of catchment area residents hospitalized with COVID-19 as the numerator and the National Center for Health Statistics vintage 2019 bridged-race postcensal population estimates as the denominator. § Descriptive analyses were conducted using all available data; however, for clinical interventions, treatments, and outcomes, only those hospitalizations with complete medical chart review and a discharge disposition (i.e., discharged alive or died during hospitalization) were included. Obesity was defined as body mass index (kg/m2) ≥95th percentile for age and sex based on CDC growth charts among children aged ≥2 years; this was not evaluated for children <2 years. All analyses were conducted using SAS statistical software (version 9.4; SAS Institute). COVID-NET activities were determined by CDC to be public health surveillance. ¶ Participating sites obtained approval for COVID-NET surveillance from their respective state and local Institutional Review Boards, as required. During March 1–July 25, 576 children hospitalized with COVID-19 were reported to COVID-NET. Infants aged <3 months accounted for 18.8% of all children hospitalized with COVID-19 (Table). The median patient age was 8 years (interquartile range [IQR] = 9 months–15 years), and 292 (50.7%) were males. Among 526 (91.3%) children for whom race and ethnicity information were reported, 241 (45.8%) were Hispanic, 156 (29.7%) were black, 74 (14.1%) were white; 24 (4.6%) were non-Hispanic Asian or Pacific Islander; and four (0.8%) were non-Hispanic American Indian/Alaska Native. TABLE Demographic and clinical characteristics of children aged <18 years hospitalized with COVID-19 — COVID-NET, 14 States,* March 1–July 25, 2020 † Characteristic No./Total no. (%) All ages 0–2 yrs 2–4 yrs 5–17 yrs Age (N = 576) 0–2 mos 108/576 (18.8) — — — 3–5 mos 20/576 (3.5) — — — 6–11 mos 29/576 (5.0) — — — 12–23 mos 31/576 (5.4) — — — 2–4 yrs 50/576 (8.7) — — — 5–11 yrs 97/576 (16.8) — — — 12–17 yrs 241/576 (41.8) — — — Age (N = 576) median (IQR) 8 yrs (9 mos–15 yrs) Sex (N = 576) Male 292/576 (50.7) 106/188 (56.4) 25/50 (50.0) 161/338 (47.6) Female 284/576 (49.3) 82/188 (43.6) 25/50 (50.0) 177/338 (52.4) Race/Ethnicity (N = 526) NH White 74/526 (14.1) 29/162 (17.9) 5/46 (10.9) 40/318 (12.6) NH Black 156/526 (29.7) 38/162 (23.5) 17/46 (37.0) 101/318 (31.8) Hispanic or Latino 241/526 (45.8) 73/162 (45.1) 18/46 (39.1) 150/318 (47.2) NH American Indian/Alaska Native 4/526 (0.8) 0/162 (—) 0/46 (—) 4/318 (1.3) NH Asian or Pacific Islander 24/526 (4.6) 13/162 (8.0) 3/46 (6.5) 8/318 (2.5) Multiple races 3/526 (0.6) 0/162 (—) 1/46 (2.2) 2/318 (0.6) Unknown 24/526 (4.6) 9/162 (5.6) 2/46 (4.3) 13/318 (4.1) Any underlying condition (N = 222) 94/222 (42.3) 14/65 (21.5) 9/24 (37.5) 71/133 (53.4) Obesity§ 42/111 (37.8) N/A 6/18 (33.3) 36/93 (38.7) Chronic lung disease 40/222 (18.0) 2/65 (3.1) 4/24 (16.7) 34/133 (25.6)   Asthma 30/222 (13.5) 1/65 (1.5) 0/24 (0) 29/133 (21.8) Prematurity (gestational age <37 weeks)¶ 10/65 (15.4) 10/65 (15.4) N/A N/A Neurologic disorder 31/222 (14.0) 6/65 (9.2) 7/24 (29.2) 18/133 (13.5) Immunocompromised condition 12/222 (5.4) 0/65 (—) 2/24 (8.3) 10/133 (7.5) Feeding tube dependent 12/222 (5.4) 4/65 (6.2) 3/24 (12.5) 5/133 (3.8) Chronic metabolic disease 10/222 (4.5) 1/65 (1.5) 0/24 (—) 9/133 (6.8)   Diabetes mellitus 6/222 (2.7) 0/65 (—) 0/24 (—) 6/133 (4.5) Blood disorders 8/222 (3.6) 0/65 (—) 0/24 (—) 8/133 (6.0)   Sickle cell disease 5/222 (2.3) 0/65 (—) 0/24 (—) 5/133 (3.8) Cardiovascular disease 7/222 (3.2) 2/65 (3.1) 2/24 (8.3) 3/133 (2.3)   Congenital heart disease 4/222 (1.8) 2/65 (3.1) 1/24 (4.2) 1/133 (0.8) Any underlying condition by race/ethnicity (N = 94) NH White 14/94 (14.9) 4/14 (28.6) 0/9 (—) 10/71 (14.1) NH Black 28/94 (29.8) 3/14 (21.4) 2/9 (22.2) 23/71 (32.4) Hispanic or Latino 43/94 (45.7) 7/14 (50) 6/9 (66.7) 30/71 (42.3) NH American Indian/Alaska Native 2/94 (2.1) 0/14 (—) 0/9 (—) 2/71 (2.8) NH Asian or Pacific Islander 3/94 (3.2) 0/14 (—) 0/9 (—) 3/71 (4.2) Multiracial 1/94 (1.1) 0/14 (—) 1/9 (11.1) 0/71 (—) Unknown 3/94 (3.2) 0/14 (—) 0/9 (—) 3/71 (4.2) Signs and symptoms (N = 224) Fever/chills 121/224 (54.0) 50/67 (74.6) 13/24 (54.2) 58/133 (43.6) Inability to eat/poor feeding¶ 22/67 (32.8) 22/67 (32.8) N/A N/A Nausea/vomiting 69/224 (30.8) 14/67 (20.9) 6/24 (25.0) 49/133 (36.8) Cough 66/224 (29.5) 17/67 (25.4) 3/24 (12.5) 46/133 (34.6) Nasal congestion/rhinorrhea 53/224 (23.7) 22/67 (32.8) 5/24 (20.8) 26/133 (19.5) Shortness of breath/respiratory distress 50/224 (22.3) 9/67 (13.4) 2/24 (8.3) 39/133 (29.3) Abdominal pain 42/224 (18.8) 2/67 (3.0) 3/24 (12.5) 37/133 (27.8) Diarrhea 27/224 (12.1) 5/67 (7.5) 3/24 (12.5) 19/133 (14.3) Hospitalization length of stay (N = 208) median days (IQR) 2.5 (1—5) 2 (1—2) 3 (1—4) 3 (2—6) Chest radiograph findings (N = 67) Infiltrate/consolidation 44/67 (65.7) 8/15 (53.3) 3/9 (33.3) 33/43 (76.7) Bronchopneumonia/pneumonia 14/67 (20.9) 2/15 (13.3) 0/9 (—) 12/43 (27.9) Pleural effusion 4/67 (6.0) 0/15 (—) 1/9 (11.1) 3/43 (7.0) Chest CT findings (N = 14) Ground glass opacities 10/14 (71.4) 1/1 (100.0) 1/1 (100.0) 8/12 (66.7) Infiltrate/consolidation 7/14 (50.0) 0/1 (—) 0/1 (—) 7/12 (58.3) Bronchopneumonia/pneumonia 4/14 (28.6) 0/1 (—) 0/1 (—) 4/12 (33.3) Pleural effusion 3/14 (21.4) 0/1 (—) 0/1 (—) 3/12 (25.0) COVID-19 investigational treatment (N = 208)** Received treatment 12/208 (5.8) 0/61 (—) 0/24 (—) 12/123 (9.8)   Remdesivir 9/208 (4.3) 0/61 (—) 0/24 (—) 9/123 (7.3)   Azithromycin†† 6/208 (2.9) 0/61 (—) 0/24 (—) 6/123 (4.9)   Hydroxychloroquine 4/208 (1.9) 0/61 (—) 0/24 (—) 4/123 (3.3)   Convalescent plasma 1/208 (0.5) 0/61 (—) 0/24 (—) 1/123 (0.8)   Lopinavir-ritonavir§§ 1/208 (0.5) 0/61 (—) 0/24 (—) 1/123 (0.8) ICU admission (N = 208) 69/208 (33.2) 19/61 (31.1) 9/24 (37.5) 41/123 (33.3) ICU length of stay median days (IQR) 2 (1—5) 1 (1—3) 2 (2—5) 3.5 (1—7) Interventions (N = 208) ¶¶ Invasive mechanical ventilation*** 12/207 (5.8) 0/61 (—) 4/24 (16.7) 8/122 (6.6) BIPAP/CPAP*** 8/207 (3.9) 2/61 (3.3) 2/24 (8.3) 4/122 (3.3) High flow nasal cannula*** 5/207 (2.4) 1/61 (1.6) 1/24 (4.2) 3/122 (2.5) Systemic steroids 19/208 (9.1) 1/61 (1.6) 4/24(16.7) 14/123 (11.4) IVIG 14/208 (6.7) 1/61 (1.6) 5/24 (20.8) 8/123 (6.5) Vasopressor 10/208 (4.8) 0/61 (—) 0/24 (—) 10/123 (8.1) New clinical discharge diagnoses (N = 208) Pneumonia 23/208 (11.1) 2/61 (3.3) 2/24 (8.3) 19/123 (15.4) Multisystem inflammatory syndrome in children (MIS-C)††† 9/83 (10.8) 1/15 (6.7) 5/15 (33.3) 3/53 (5.7) Acute respiratory failure 10/208 (4.8) 0/61 (—) 3/24 (12.5) 7/123 (5.7) Acute kidney injury 6/208 (2.9) 0/61 (—) 0/24 (—) 6/123 (4.9) Diabetic ketoacidosis 6/208 (2.9) 0/61 (—) 0/24 (—) 6/123 (4.9) Acute respiratory distress syndrome 4/208 (1.9) 1/61 (1.6) 0/24 (—) 3/123 (2.4) Died during hospitalization (N = 208) 1/208 (0.5) 0/61 (—) 0/24 (—) 1/123 (0.8) Abbreviations: BIPAP = bilevel positive airway pressure; CT = computed tomography; CPAP = continuous positive airway pressure; COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19–Associated Hospitalization Surveillance Network; ICU = intensive care unit; IQR = interquartile range; IVIG = intravenous immune globulin; N/A = not applicable; NH = non-Hispanic. * California, Connecticut, Colorado, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah. † Analyses were conducted on all available data; however, for hospitalization length of stay, radiology findings, treatments, ICU admission, interventions, new clinical diagnoses, and outcome, only cases with a complete medical chart review and a discharge disposition (i.e. discharged alive or died during hospitalization) were included. § Obesity was defined as body mass index (kg/m2) ≥95th percentile for age and sex based on CDC growth charts among children aged ≥2 years; this was not evaluated for children <2 years. ¶ Data collected only on children aged <2 years. ** Not mutually exclusive treatment categories. †† Given with at least one other COVID-19 investigational treatment. §§ Not given for human immunodeficiency virus infection. ¶¶ Two hospitalized children received extracorporeal membrane oxygenation (1 each aged <2 years and 5–17 years). None received renal replacement therapy. *** Highest level of respiratory support for each case that needed respiratory support. ††† Since June 18, a discharge diagnosis of multisystem inflammatory syndrome in children (MIS-C) was systematically collected through COVID-NET. The cumulative COVID-19–associated hospitalization rate among children aged <18 years during the surveillance period was 8.0 per 100,000 and was highest among children aged <2 years (24.8); rates were substantially lower in children aged 2–4 years (4.2) and 5–17 years (6.4) (Figure 1). Overall weekly hospitalization rates among children increased steadily during the surveillance period (from 0.1 to 0.4 per 100,000, with a weekly high of 0.7 per 100,000; trend test, p<0.001) (Figure 1). COVID-19–associated hospitalization rates were higher among Hispanic and black children than among white children (Figure 2); the rates among Hispanic and black children were nearly eight times and five times, respectively, the rate in white children. FIGURE 1 Cumulative (A) and weekly (B) COVID-19–associated hospitalization rates * ,† among children aged <18 years, by age group — COVID-NET, 14 states § , March 1–July 25, 2020 ¶ Abbreviation: COVID-NET = Coronavirus Disease 2019–Associated Hospitalization Surveillance Network. * Number of children in each age group hospitalized with COVID-19 per 100,000 population. † Figure B shows the 3-week moving average of weekly hospitalization rates for children in each age group hospitalized with COVID-19 per 100,000 population. A trend test was conducted using weighted linear regression, where the weight for each week was the inverse of the variance. Trend test overall (<18 years): p-value <0.001. § Counties included in COVID-NET surveillance: California (Alameda, Contra Costa, and San Francisco counties); Colorado (Adams, Arapahoe, Denver, Douglas, and Jefferson counties); Connecticut (New Haven and Middlesex counties); Georgia (Clayton, Cobb, DeKalb, Douglas, Fulton, Gwinnett, Newton, and Rockdale counties); Iowa (one county represented); Maryland (Allegany, Anne Arundel, Baltimore, Baltimore City, Calvert, Caroline, Carroll, Cecil, Charles, Dorchester, Frederick, Garrett, Harford, Howard, Kent, Montgomery, Prince George’s, Queen Anne’s, St. Mary’s, Somerset, Talbot, Washington, Wicomico, and Worcester counties); Michigan (Clinton, Eaton, Genesee, Ingham, and Washtenaw counties); Minnesota (Anoka, Carver, Dakota, Hennepin, Ramsey, Scott, and Washington counties); New Mexico (Bernalillo, Chaves, Dona Ana, Grant, Luna, San Juan, and Santa Fe counties); New York (Albany, Columbia, Genesee, Greene, Livingston, Monroe, Montgomery, Ontario, Orleans, Rensselaer, Saratoga, Schenectady, Schoharie, Wayne, and Yates counties); Ohio (Delaware, Fairfield, Franklin, Hocking, Licking, Madison, Morrow, Perry, Pickaway, and Union counties); Oregon (Clackamas, Multnomah, and Washington counties); Tennessee (Cheatham, Davidson, Dickson, Robertson, Rutherford, Sumner, Williamson, and Wilson counties); and Utah (Salt Lake County). ¶ Data are preliminary, and case counts and rates for recent hospital admissions are subject to lag. As data are received each week, previous case counts and rates are updated accordingly. The figure is a line graph consisting of two sections showing the cumulative and weekly COVID-19–associated hospitalization rates among U.S. children aged <18 years, by age group in the 14 states participating in the Coronavirus Disease 2019–Associated Hospitalization Surveillance Network. FIGURE 2 Cumulative COVID-19–associated hospitalization rates* among children aged <18 years, by age group and race/ethnicity — COVID-NET, 14 states † , March 1–July 25, 2020 § , ¶ Abbreviation: COVID-NET = Coronavirus Disease 2019–Associated Hospitalization Surveillance Network. * Number of children aged <18 years hospitalized with COVID-19 per 100,000 population. † Counties included in COVID-NET surveillance: California (Alameda, Contra Costa, and San Francisco counties); Colorado (Adams, Arapahoe, Denver, Douglas, and Jefferson counties); Connecticut (New Haven and Middlesex counties); Georgia (Clayton, Cobb, DeKalb, Douglas, Fulton, Gwinnett, Newton, and Rockdale counties); Iowa (one county represented); Maryland (Allegany, Anne Arundel, Baltimore, Baltimore City, Calvert, Caroline, Carroll, Cecil, Charles, Dorchester, Frederick, Garrett, Harford, Howard, Kent, Montgomery, Prince George’s, Queen Anne’s, St. Mary’s, Somerset, Talbot, Washington, Wicomico, and Worcester counties); Michigan (Clinton, Eaton, Genesee, Ingham, and Washtenaw counties); Minnesota (Anoka, Carver, Dakota, Hennepin, Ramsey, Scott, and Washington counties); New Mexico (Bernalillo, Chaves, Dona Ana, Grant, Luna, San Juan, and Santa Fe counties); New York (Albany, Columbia, Genesee, Greene, Livingston, Monroe, Montgomery, Ontario, Orleans, Rensselaer, Saratoga, Schenectady, Schoharie, Wayne, and Yates counties); Ohio (Delaware, Fairfield, Franklin, Hocking, Licking, Madison, Morrow, Perry, Pickaway, and Union counties); Oregon (Clackamas, Multnomah, and Washington counties); Tennessee (Cheatham, Davidson, Dickson, Robertson, Rutherford, Sumner, Williamson, and Wilson counties); and Utah (Salt Lake County). § Data are preliminary, and case counts and rates for recent hospital admissions are subject to lag. As data are received each week, prior case counts and rates are updated accordingly. As of July 25, 2020, 50 (8.7%) of 576 pediatric hospitalized cases were missing data on race and ethnicity. ¶ Rates are not shown among non-Hispanic Asian or Pacific Islanders and non-Hispanic American Indian/Alaska Natives because of small case counts, leading to unstable estimates. All non-Hispanic American Indian/Alaska Native hospitalized children were aged 5–17 years. The figure is a bar chart showing the cumulative COVID-19–associated hospitalization rates among U.S. children aged <18 years during March 1–July 25, 2020, by age group and race/ethnicity in the 14 states participating in the Coronavirus Disease 2019–Associated Hospitalization Surveillance Network. Among 222 (38.5%) of 576 children with information on underlying medical conditions, 94 (42.3%) had one or more underlying conditions (Table). The most prevalent conditions included obesity (37.8%), chronic lung disease (18.0%), and prematurity (gestational age <37 weeks at birth, collected only for children aged <2 years) (15.4%). Hispanic and black children had higher prevalences of underlying conditions (45.7% and 29.8%, respectively) compared with white children (14.9%). Reported signs and symptoms upon hospital admission differed by age: fever or chills were the most common sign and symptom overall (54%) and were most prevalent among children aged <2 years (74.6%). Gastrointestinal symptoms, including nausea or vomiting, abdominal pain, or diarrhea, were reported by 42% of hospitalized children overall. A medical chart review was completed for 208 (36.1%) children. Median duration of hospitalization was 2.5 days (IQR = 1–5 days). Among 67 children who had a chest radiograph during hospitalization, 44 (65.7%) radiographs showed an infiltrate or consolidation. Among 14 children with chest computed tomography results available, ground-glass opacities (a nonspecific sign indicating infection or alveolar disease) was reported in 10. COVID-19 investigational treatments were only administered to 12 (5.8%) children, all aged 5–17 years; nine received remdesivir. Intravenous immunoglobulin was received by 14 of 208 (6.7%) children. Sixty-nine children (33.2%) were admitted to the ICU for a median of 2 days (IQR = 1–5 days). Invasive mechanical ventilation was required by 12 (5.8%) of 207 children. Since June 18, a discharge diagnosis of multisystem inflammatory syndrome in children (MIS-C) has been systematically collected**; overall, nine (10.8%) of 83 children with completed chart reviews for whom information about MIS-C was systematically collected received a diagnosis of MIS-C. Among 208 children with a discharge disposition, one child (0.5%) with multiple underlying conditions died during hospitalization. Discussion Since March 1, 2020, COVID-NET has identified 576 pediatric COVID-19–associated hospitalizations. Although the cumulative COVID-19–associated hospitalization rate among children is low compared with that among adults, weekly hospitalization rates in children increased during the surveillance period. Children can develop severe COVID-19 illness; during the surveillance period, one in three children were admitted to the ICU. Hispanic and black children had the highest rates of COVID-19–associated hospitalization. Continued surveillance will allow for further characterization of the burden and outcomes of COVID-19–associated hospitalizations among children. These data will help to better define the clinical spectrum of disease in children and the contributions of race and ethnicity and underlying medical conditions to hospitalizations and outcomes. Reasons for disparities in COVID-19-associated hospitalization rates by race and ethnicity are not fully understood. This report found the highest rates of COVID-19-associated hospitalization among Hispanic children. Similarly, a recent study from the Baltimore-District of Columbia region found a higher prevalence of SARS-CoV-2 infection in the Hispanic community compared with that in other racial and ethnic communities ( 4 ). Although hospitalization rates were lower for Hispanic persons than for black and white persons, hospitalized Hispanic patients were more likely to be younger (aged <44 years) ( 4 ). It has been hypothesized that Hispanic adults might be at increased risk for SARS-CoV-2 infection because they are overrepresented in frontline (e.g., essential and direct-service) occupations with decreased opportunities for social distancing, which might also affect children living in those households ( 4 ). During the 2009 influenza A H1N1 pandemic, pediatric mortality rates also were higher among underrepresented ethnic groups in a study from England ( 5 ). Forty-two percent of children in this analysis had one or more underlying medical conditions, with higher prevalences among Hispanic and black children. This suggests that the presence of underlying conditions place children at higher risk for COVID-19-associated hospitalizations and that observed disparities might in part be related to the higher prevalence of underlying conditions among hospitalized Hispanic and black children compared with those among white children. This study, along with other studies of hospitalized children with COVID-19, found that obesity was the most prevalent underlying medical condition ( 6 , 7 ). Childhood obesity affects almost one in five U.S. children and is more prevalent in black and Hispanic children ( 8 ); therefore, understanding the underlying pathophysiologic association between obesity and SARS-CoV-2 infection is important to identifying possible clinical interventions and preventive strategies to reduce the risk for hospitalization. This report and others have found that, although one third of children hospitalized with COVID-19 were admitted to the ICU, the case-fatality rate remains low, even among children hospitalized with more severe COVID-19–associated complications, such as MIS-C ( 6 , 7 , 9 ). By comparison, among U.S. children hospitalized with seasonal influenza virus infection, estimates of ICU admissions have ranged from 16% to 25% among hospitalized children without and with underlying medical conditions, respectively, and reports of in-hospital deaths also are rare (<1%) ( 10 ). The percentage of ICU admission was similar among children (33.2%) and adults (32.0%) reported to COVID-NET; however, invasive mechanical ventilation was required less frequently in children (5.8%) than in adults (18.6%) ( 3 ). Continued monitoring of hospitalizations, ICU admissions, and mortality among children is important to understand potential risk factors for severe outcomes. The findings in this report are subject to at least five limitations. First, laboratory confirmation is dependent on clinician-ordered SARS-CoV-2 molecular testing. Rates likely are underestimates; cases can be missed because of test availability, test performance, and provider or facility testing practices. Second, hospitalization rates by age group and race/ethnicity are preliminary and might change as additional cases are identified during the surveillance period. Third, analysis of interventions, treatments, and outcomes was based on a convenience sample of children with a final disposition and complete chart reviews. A higher proportion of included children were aged <6 months, and two sites contributed more than half of cases; however, compared with other single-center or state-based studies, COVID-NET is more geographically and racially diverse ( 2 ). Approximately 60% of pediatric hospitalizations reported to COVID-NET have not had a chart review, and this sample might be biased. In the future, COVID-NET plans to have complete, population-based data on hospitalized children. Finally, COVID-NET did not systematically collect information on MIS-C until June 18. In addition, given that molecular tests can miss approximately half of patients with MIS-C despite serologic or epidemiologic evidence of a past SARS-CoV-2 infection ( 9 ), COVID-NET surveillance likely underestimates the percentage of MIS-C cases among SARS-CoV-2 infections in children. Using a multisite, geographically diverse network, this report found that children with SARS-CoV-2 infection can have severe illness requiring hospitalization and intensive care. Improved understanding of the social determinants of health is needed to inform and reduce disparities as evidenced by pediatric COVID-19-associated hospitalization rates. Similar to the general population, children should be encouraged to wash their hands often and continue social distancing, and children aged ≥2 years should wear a mask when around persons outside of their families to reduce the risk for SARS-CoV-2 infection and transmission to others. Ongoing monitoring of hospitalization rates, clinical characteristics, ICU admission, and outcomes in the pediatric population is important to further characterize the morbidity and mortality of COVID-19 in children. Summary What is already known about this topic? Most reported SARS-CoV-2 infections in children aged <18 years are asymptomatic or mild. Less is known about severe COVID-19 in children requiring hospitalization. What is added by this report? Analysis of pediatric COVID-19 hospitalization data from 14 states found that although the cumulative rate of COVID-19–associated hospitalization among children (8.0 per 100,000 population) is low compared with that in adults (164.5), one in three hospitalized children was admitted to an intensive care unit. What are the implications for public health practice? Children are at risk for severe COVID-19. Public health authorities and clinicians should continue to track pediatric SARS-CoV-2 infections. Reinforcement of prevention efforts is essential in congregate settings that serve children, including childcare centers and schools.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Preliminary evidence on long COVID in children

                Bookmark

                Author and article information

                Contributors
                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb Mortal Wkly Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                10 September 2021
                10 September 2021
                : 70
                : 36
                : 1255-1260
                Affiliations
                CDC COVID-19 Response Team; Epidemic Intelligence Service, CDC; General Dynamics Information Technology, Atlanta, Georgia; California Emerging Infections Program, Oakland, California; Career Epidemiology Field Officer Program, CDC; University of California, Berkeley School of Public Health, Berkeley, California; Colorado Department of Public Health and Environment; Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut; Emory University School of Medicine, Atlanta, Georgia; Georgia Emerging Infections Program, Georgia Department of Health; Atlanta Veterans Affairs Medical Center, Atlanta, Georgia; Iowa Department of Health; Michigan Department of Health and Human Services; Minnesota Department of Health; New Mexico Emerging Infections Program, New Mexico Department of Health, Santa Fe, New Mexico; New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, New Mexico; New York State Department of Health; University of Rochester School of Medicine and Dentistry, Rochester, New York; Rochester Emerging Infections Program, University of Rochester Medical Center, Rochester, New York; Ohio Department of Health; Public Health Division, Oregon Health Authority; Vanderbilt University Medical Center, Nashville, Tennessee; Salt Lake County Health Department, Salt Lake City, Utah; Utah Department of Health.
                California Emerging Infections Program
                Colorado Department of Public Health & Environment
                Colorado Department of Public Health & Environment
                Georgia Emerging Infections Program,
                Georgia Department of Health and Foundation for Atlanta Veterans Education and Research, Decatur, Georgia, and Atlanta Veterans Affairs Medical Center, Atlanta, Georgia
                Georgia Emerging Infections Program
                Georgia Department of Health, and Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
                Minnesota Department of Health
                Minnesota Department of Health
                New Mexico Emerging Infections Program
                New Mexico Emerging Infections Program
                New York State Department of Health
                New York State Department of Health
                University of Rochester School of Medicine and Dentistry, Rochester, New York
                University of Rochester School of Medicine and Dentistry, Rochester, New York
                Public Health Division, Oregon Health Authority
                Public Health Division, Oregon Health Authority
                Vanderbilt University Medical Center, Nashville, Tennessee
                Salt Lake County Health Department, Salt Lake City, Utah
                Salt Lake County Health Department, Salt Lake City, Utah
                Author notes
                Corresponding author: Miranda J. Delahoy; MDelahoy@ 123456cdc.gov .
                Article
                mm7036e2
                10.15585/mmwr.mm7036e2
                8437052
                34499627
                2b09e5ec-a063-4541-ba49-f45cbd334ba9

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article